Hologic Inc. (HOLX) VP Sells $1,258,800.00 in Stock
Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 31,470 shares of the firm’s stock in a transaction on Monday, October 10th. The stock was sold at an average price of $40.00, for a total transaction of $1,258,800.00. Following the completion of the sale, the vice president now owns 17,005 shares in the company, valued at $680,200. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Hologic Inc. (NASDAQ:HOLX) traded up 0.31% during midday trading on Wednesday, hitting $38.81. 1,368,877 shares of the company were exchanged. Hologic Inc. has a one year low of $31.84 and a one year high of $41.66. The stock has a market capitalization of $10.77 billion, a PE ratio of 42.79 and a beta of 1.00. The firm’s 50-day moving average price is $38.49 and its 200-day moving average price is $36.32.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. The firm had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.43 earnings per share. Equities research analysts anticipate that Hologic Inc. will post $1.94 earnings per share for the current year.
Several research firms have issued reports on HOLX. Leerink Swann restated an “outperform” rating and issued a $46.00 price target on shares of Hologic in a research report on Monday, October 3rd. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 price target on the stock in a research report on Wednesday, September 28th. Barclays PLC upgraded shares of Hologic from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $42.00 to $44.00 in a research report on Friday, September 23rd. Piper Jaffray Cos. set a $44.00 price target on shares of Hologic and gave the stock a “hold” rating in a research report on Sunday, August 28th. Finally, RBC Capital Markets reiterated a “sector perform” rating and set a $39.00 target price (up from $37.00) on shares of Hologic in a research report on Monday, August 1st. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $42.71.
A number of large investors have recently made changes to their positions in HOLX. HBK Investments L P increased its stake in shares of Hologic by 140.0% in the first quarter. HBK Investments L P now owns 433,900 shares of the company’s stock worth $14,970,000 after buying an additional 253,100 shares during the last quarter. Hancock Holding Co. increased its stake in shares of Hologic by 2.2% in the first quarter. Hancock Holding Co. now owns 46,261 shares of the company’s stock worth $1,596,000 after buying an additional 977 shares during the last quarter. Bogle Investment Management L P DE increased its stake in shares of Hologic by 747.3% in the first quarter. Bogle Investment Management L P DE now owns 339,755 shares of the company’s stock worth $11,721,000 after buying an additional 299,655 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock worth $80,187,000 after buying an additional 819,646 shares during the last quarter. Finally, Fairpointe Capital LLC increased its stake in shares of Hologic by 40.3% in the first quarter. Fairpointe Capital LLC now owns 20,900 shares of the company’s stock worth $721,000 after buying an additional 6,000 shares during the last quarter. Hedge funds and other institutional investors own 94.51% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.